{"id":6112,"date":"2022-10-03T06:30:00","date_gmt":"2022-10-03T06:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realhearts-ceo-to-speak-at-the-fokus-patient-forum-on-october-5\/"},"modified":"2022-10-03T06:30:00","modified_gmt":"2022-10-03T06:30:00","slug":"realhearts-ceo-to-speak-at-the-fokus-patient-forum-on-october-5","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realhearts-ceo-to-speak-at-the-fokus-patient-forum-on-october-5\/","title":{"rendered":"Realheart’s CEO to Speak at the Fokus Patient Forum on October 5"},"content":{"rendered":"
Press Release 3 October, 2022<\/p>\n

On 5 October, Realheart's CEO Ina Laura Perkins will be presenting at the ''Transplantation Forum'' organised by Fokus Patient in collaboration with Livet som G\u00e5va and the European Society of Organ Transplantation, ESOT, at the City Conference Centre in Stockholm.<\/strong><\/div>\n

The Transplantation Forum is part of a three-day forum where healthcare professionals, patients, companies, and other interested parties can get an overview of developments and discuss current issues in the field of transplantation in Sweden and internationally.<\/span><\/span><\/span><\/span><\/p>\n

Participants include Dr Bartley Griffith, an American surgeon who recently performed a high-profile pig heart transplant for a human.<\/span><\/span><\/span><\/span><\/p>\n

Realheart's CEO Ina Laura Perkins has been invited to give a presentation entitled ''When organs are not enough'' in a section covering the future of organs and organ donation. <\/span><\/span><\/span><\/span><\/p>\n

''I look forward to telling future clients, people in healthcare and patients about Realheart and all the benefits it can offer as a complement to other options in the future. An artificial heart can easily be stored and taken straight off the shelf, making it urgently available \u2013 both as a permanent solution and as a bridge between the human heart and other alternatives. The patient also does not need to take immunosuppressive drugs for the rest of their life, as is the case after a transplant'' said Ina Laura Perkins. <\/span><\/span><\/span><\/span><\/p>\n

The full programme is available <\/span>here<\/span><\/a>. <\/span><\/span><\/span><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30\u00a0732, email:\u00a0ca@skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n